Controlled-release nano medicine available for targeted application to neurodegenerative diseases

A neurodegenerative and disease-related technology, applied in the field of medicine, can solve the problems of drug limitations and inability to meet the needs of neurodegenerative diseases with high efficiency, sustained release, and targeted treatment, so as to reduce damage and burden, have no immunogenicity, The effect of high biosafety

Active Publication Date: 2017-06-09
INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] 2. Limitations of the application of existing drugs
[0013] To sum up, neither molecular drugs nor existing nano-drugs can meet the needs of neurodegenerative diseases with high efficiency, sustained release and targeted treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Controlled-release nano medicine available for targeted application to neurodegenerative diseases
  • Controlled-release nano medicine available for targeted application to neurodegenerative diseases
  • Controlled-release nano medicine available for targeted application to neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0119] Embodiment 1: Preparation of nanoparticles loaded with acetylcholine (Ach)

[0120] In this embodiment, human serum albumin (HSA) is used as the nano-carrier material to wrap and load acetylcholine. The active ingredient used is acetylcholine chloride, the good solvent selected is 10mmol / L sodium chloride solution, the poor solvent selected is ethanol, the cross-linking agent selected is 10% glutaraldehyde, and the targeted molecule selected is Wen-80 uses human serum albumin (HSA) nanoparticles as the carrier material. The preparation process is as follows.

[0121] Step (1): Prepare HSA drug-loaded nanoparticles by anti-solvent method: Dissolve 20mg HSA and 10mg ACh in 1mL sodium chloride solution (10mmol / L), filter with a 0.22μm water filter membrane, and at 600rpm, Add this solution dropwise to 10 mL of ethanol at a rate of 50 μL / min; after the dropwise addition, increase the stirring speed to 800 rpm, add 20 μL of 10% glutaraldehyde, and react in the dark for 24 ...

Embodiment 2

[0133] Embodiment 2: Preparation of nanoparticles loaded with rivastigmine (RT)

[0134] In this example, human serum albumin (HSA) nanoparticles were used as drug carriers to prepare nanoparticles loaded with rivastigmine (RT). The active ingredient used is rivastigmine bitartrate, the good solvent selected is the sodium chloride solution of 10mmol / L, the poor solvent selected is dehydrated alcohol (purity is greater than 99.7%), and the cross-linking agent selected is 10% Glutaraldehyde, the selected targeting molecule is Tween-80. The preparation process is as follows.

[0135] (1) Prepare HSA drug-loaded nanoparticles by anti-solvent method: dissolve 20mg HSA and 10mg RT in 1ml sodium chloride solution (10mmol / L), adjust the pH of the solution to 8.3 with 0.1mol / L sodium hydroxide solution, After filtering with a 0.22 μm water-based filter membrane, add the solution dropwise to 10 mL of absolute ethanol at a rate of 50 μL / min at a speed of 600 rpm; after the addition, in...

Embodiment 3

[0138] Example 3: Structural Characterization of Nanoparticles

[0139] (1) Ultraviolet absorption spectrum analysis

[0140] Respectively ACh aqueous solution, HSA aqueous solution, blank HSA nanoparticles that are not loaded with active ingredients and unmodified Tween-80 (the preparation process refers to the step (1) of Example 1), and the unmodified HSA nanoparticles prepared by the step (1) of Example 1. The HSA-ACh nanoparticles modified with Tween-80 were analyzed by ultraviolet absorption spectrum, and the ultraviolet absorption curve of the sample was as follows: Figure 6 shown. HSA solution has obvious characteristic absorption peak near 280nm (curve 1), but Ach solution has no absorption near 280nm (curve 2). After HSA forms blank nanoparticles, the absorption peak near 280nm is still clearly visible (curve 3); while the HSA nanoparticles loaded with Ach, the absorption peak near 280nm is significantly reduced (curve 4). Therefore, when HSA nanoparticles are do...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to a controlled-release nano medicine available for targeted application to neurodegenerative diseases, in particular to a nano particle. The nano particle comprises a carrier material, active components and target modules, wherein the carrier material is human serum albumin, and the active components are capable of preventing and / or treating the neurodegenerative diseases. The invention further relates to a nano particle preparation method, a nano-particle-containing pharmaceutical composition and application of the nano particle or the pharmaceutical composition to preparation of medicines for preventing and / or treating the neurodegenerative diseases of subjects.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a nanoparticle comprising a carrier material, an active ingredient and a targeting molecule, the carrier material is human serum albumin, and the active ingredient is capable of preventing and / or treating neurodegenerative diseases active ingredient. The present invention also relates to a method for preparing the nanoparticle, a pharmaceutical composition containing the nanoparticle, and the use of the nanoparticle or the pharmaceutical composition in the preparation of a medicament for preventing and / or treating neurodegenerative diseases in a subject use in . Background technique [0002] 1. The cholinergic hypothesis of Alzheimer's disease [0003] Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive decline in memory and cognitive abilities. At present, there is still no clear conclusion on the etiology of AD, mainly focusing on the choline...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/50A61K47/42A61K45/00A61K31/221A61P25/28A61P25/16A61P25/14A61P25/00A61P37/02A61P21/00
CPCA61K45/00A61K9/5052A61K31/221A61K31/27A61K31/704A61K31/55A61K31/445A61P25/00A61K9/5169
Inventor 王永安杨军范丽雪骆媛李万华隋昕
Owner INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap